Daré Bioscience enters into ATM equity offering program with Stifel and Cantor

Dare Bioscience, Inc.

Entered into sales agreement with Stifel and Cantor for at-the-market equity offering of common stock.
Commission of 3.0% of gross proceeds payable to sales agents.
Shares sold under existing shelf registration statement filed March 30, 2021.
Company sets parameters including maximum shares, time period, and minimum price.
Sales may be made on Nasdaq or in privately negotiated transactions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Dare Bioscience, Inc. entered into Sales Agreement with Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co. (effective 2023-03-31).

Action: entry
Agreement: atm program
Counterparty: Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co.
Effective: 2023-03-31

Exact text from the filing

On March 31, 2023, Daré Bioscience, Inc. (“we,” “us,” “our”), entered into a sales agreement (the “Sales Agreement”) with Stifel, Nicolaus & Company, Incorporated (“Stifel Nicolaus”) and Cantor Fitzgerald & Co. (“Cantor”) to sell shares of our common stock from time to time through an “at-the-market” equity offering program under which Stifel Nicolaus and Cantor will act as our sales agents (each individually a “Sales Agent” and together, the “Sales Agents”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-010311

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.